Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher.

Glassman FY, Schneider JL, Ramakrishnan R, Dingman RK, Ramanathan M, Bankert RB, Balu-Iyer SV.

J Pharm Sci. 2018 Apr 9. pii: S0022-3549(18)30200-4. doi: 10.1016/j.xphs.2018.03.027. [Epub ahead of print]

PMID:
29649469
2.

Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses.

Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr, Minderman H, Wallace PK, Odunsi K, Balu-Iyer SV, Bankert RB.

Cancer Immunol Res. 2018 Feb;6(2):236-247. doi: 10.1158/2326-6066.CIR-17-0113. Epub 2018 Jan 4.

3.

Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.

Burack WR, Spence JM, Spence JP, Spence SA, Rock PJ, Shenoy GN, Shultz LD, Bankert RB, Bernstein SH.

Blood Adv. 2017 Jul 7;1(16):1263-1273. doi: 10.1182/bloodadvances.2017005892. eCollection 2017 Jul 11.

4.

Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade.

Kelleher RJ Jr, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, Iyer V, Fathallah AM, Berenson CS, Wallace PK, Tario J, Odunsi K, Bankert RB.

Cancer Immunol Res. 2015 Nov;3(11):1269-78. doi: 10.1158/2326-6066.CIR-15-0086. Epub 2015 Jun 25.

5.

Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB.

Cancer Immun. 2013 May 31;13:11. Print 2013.

6.

Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.

7.

Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.

Fathallah AM, Bankert RB, Balu-Iyer SV.

AAPS J. 2013 Oct;15(4):897-900. doi: 10.1208/s12248-013-9510-6. Epub 2013 Jul 16. Review.

8.

Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.

Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ Jr, Bankert RB, Balu-Iyer SV.

J Biol Chem. 2013 Jun 14;288(24):17051-6. doi: 10.1074/jbc.C112.396325. Epub 2013 May 6.

9.

Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.

Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV.

J Pharm Sci. 2012 Jun;101(6):2055-65. doi: 10.1002/jps.23091. Epub 2012 Mar 2.

10.

Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor.

Lehman HK, Simpson-Abelson MR, Conway TF Jr, Kelleher RJ Jr, Bernstein JM, Bankert RB.

J Assoc Res Otolaryngol. 2012 Jun;13(3):423-35. doi: 10.1007/s10162-012-0313-8. Epub 2012 Feb 4.

11.

Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII.

Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV.

J Pharm Sci. 2012 Jan;101(1):48-55. doi: 10.1002/jps.22746. Epub 2011 Sep 23.

12.

Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis.

Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R, Yokota SJ.

PLoS One. 2011;6(9):e24420. doi: 10.1371/journal.pone.0024420. Epub 2011 Sep 15.

13.

T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB.

Cancer Microenviron. 2010 Mar 31;3(1):29-47. doi: 10.1007/s12307-010-0044-5.

14.

Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV.

Clin Immunol. 2011 Feb;138(2):135-45. doi: 10.1016/j.clim.2010.10.006. Epub 2010 Nov 20.

15.

Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors.

Barnas JL, Simpson-Abelson MR, Brooks SP, Kelleher RJ Jr, Bankert RB.

J Immunol. 2010 Sep 1;185(5):2681-92. doi: 10.4049/jimmunol.1000896. Epub 2010 Aug 4.

16.

Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice.

Bernstein JM, Brooks SP, Lehman HK, Pope L, Sands A, Shultz LD, Bankert RB.

Ann Otol Rhinol Laryngol. 2009 Dec;118(12):866-75.

17.

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, Odunsi K, Demmy TL, Yokota SJ, Loyall JL, Kelleher RJ Jr, Balu-Iyer S, Bankert RB.

Clin Immunol. 2009 Jul;132(1):71-82. doi: 10.1016/j.clim.2009.03.516. Epub 2009 Apr 22.

18.

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ Jr, Bankert RB, Bernstein SH.

Blood. 2009 Apr 16;113(16):3809-12. doi: 10.1182/blood-2008-10-185280. Epub 2009 Feb 4.

19.

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.

Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF Jr, Kelleher RJ Jr, Shultz LD, Barcos M, Bankert RB.

J Immunol. 2008 May 15;180(10):7009-18.

20.

Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment.

Simpson-Abelson M, Bankert RB.

Expert Opin Ther Targets. 2008 Apr;12(4):477-90. doi: 10.1517/14728222.12.4.477 . Review.

PMID:
18348683
21.

Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells.

Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB.

J Immunol. 2007 May 1;178(9):5552-62.

22.
24.
25.

Human nasal polyp microenvironment maintained in viable and functional states as xenografts in SCID mice.

Bernstein JM, Broderick L, Parsons RR, Bankert RB.

Ann Otol Rhinol Laryngol. 2006 Jan;115(1):65-73.

PMID:
16466102
26.

IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells.

Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, Bankert RB.

Clin Immunol. 2006 Feb-Mar;118(2-3):159-69. Epub 2005 Nov 3.

PMID:
16271513
27.

B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells.

Lou Q, Conway TF Jr, Egilmez NK, Loyall JL, Bernstein SH, Kelleher RJ Jr, Bankert RB.

Clin Immunol. 2006 Jan;118(1):66-76. Epub 2005 Sep 26.

PMID:
16185929
28.

CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.

Sabel MS, Hess SD, Egilmez NK, Conway TF Jr, Chen FA, Bankert RB.

Cancer Immunol Immunother. 2005 Oct;54(10):944-52. Epub 2005 Apr 22.

29.

Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells.

Broderick L, Yokota SJ, Reineke J, Mathiowitz E, Stewart CC, Barcos M, Kelleher RJ Jr, Bankert RB.

J Immunol. 2005 Jan 15;174(2):898-906.

30.

Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells.

Lou Q, Kelleher RJ Jr, Sette A, Loyall J, Southwood S, Bankert RB, Bernstein SH.

Blood. 2004 Aug 1;104(3):752-9. Epub 2004 Mar 30.

31.

Liposome-mediated cytokine gene delivery to human tumor xenografts.

Eğilmez NK, Bankert RB.

Methods Enzymol. 2003;373:529-35. No abstract available.

PMID:
14714425
32.

Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.

Anderson TM, Hess SD, Egilmez NK, Nwogu CE, Lenox JM, Bankert RB.

J Cancer Res Clin Oncol. 2003 Oct;129(10):565-8. Epub 2003 Aug 16.

PMID:
12923636
33.

The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients.

Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ.

J Liposome Res. 2002 Feb-May;12(1-2):1-3. Review.

PMID:
12604032
35.
36.

Tumor vaccination with cytokine-encapsulated microspheres.

Egilmez NK, Jong YS, Mathiowitz E, Bankert RB.

Methods Mol Med. 2003;75:687-96. No abstract available.

PMID:
12407772
38.
39.

Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases.

Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK.

Surgery. 2001 Sep;130(3):470-8.

PMID:
11562672
40.

Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.

Sugano M, Conway TF Jr, Kelleher RJ Jr, Sugiyama Y, Chen FA, Bankert RB, Bernstein SH.

J Exp Clin Cancer Res. 2001 Jun;20(2):175-82.

PMID:
11484971
42.

Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies.

Bankert RB, Egilmez NK, Hess SD.

Trends Immunol. 2001 Jul;22(7):386-93. Review.

PMID:
11429323
43.
44.

Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12.

Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB.

J Immunother. 2001 Jan-Feb;24(1):37-45.

PMID:
11211147
45.
46.

In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB.

Cancer Res. 2000 Jul 15;60(14):3832-7.

47.

Patient immune response to tumors monitored using SCID mouse models.

Bankert RB, Chen FA, Sugiyama Y, Egilmez N.

Immunol Invest. 2000 May;29(2):171-6. Review. No abstract available.

PMID:
10854186
49.

CD40 expression on human lung cancer correlates with metastatic spread.

Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB.

Cancer Immunol Immunother. 2000 May;49(2):101-8.

PMID:
10823420
50.

Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model.

Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB.

J Immunother. 2000 Mar-Apr;23(2):190-5.

PMID:
10746545

Supplemental Content

Loading ...
Support Center